177 related articles for article (PubMed ID: 28440528)
1. [Effect of ASCT2 gene knock-down by shRNA on biological behaviors of colorectal cancer cells].
Cai C; Zeng B; Zeng J; Xin H; Tang C
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Apr; 20(4):450-454. PubMed ID: 28440528
[TBL] [Abstract][Full Text] [Related]
2. Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development.
Wang Q; Hardie RA; Hoy AJ; van Geldermalsen M; Gao D; Fazli L; Sadowski MC; Balaban S; Schreuder M; Nagarajah R; Wong JJ; Metierre C; Pinello N; Otte NJ; Lehman ML; Gleave M; Nelson CC; Bailey CG; Ritchie W; Rasko JE; Holst J
J Pathol; 2015 Jul; 236(3):278-89. PubMed ID: 25693838
[TBL] [Abstract][Full Text] [Related]
3. Topotecan induces hepatocellular injury via ASCT2 mediated oxidative stress.
Zhou G; Qin M; Zhang X; Yang J; Yu H
Gastroenterol Hepatol; 2021 Jan; 44(1):1-12. PubMed ID: 33039171
[TBL] [Abstract][Full Text] [Related]
4. Topotecan induces apoptosis via ASCT2 mediated oxidative stress in gastric cancer.
Wang L; Liu Y; Zhao TL; Li ZZ; He JY; Zhang BJ; Du HZ; Jiang JW; Yuan ST; Sun L
Phytomedicine; 2019 Apr; 57():117-128. PubMed ID: 30668314
[TBL] [Abstract][Full Text] [Related]
5. Clinical Role of ASCT2 (SLC1A5) in KRAS-Mutated Colorectal Cancer.
Toda K; Nishikawa G; Iwamoto M; Itatani Y; Takahashi R; Sakai Y; Kawada K
Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28749408
[TBL] [Abstract][Full Text] [Related]
6. Targeting of glutamine transporter ASCT2 and glutamine synthetase suppresses gastric cancer cell growth.
Ye J; Huang Q; Xu J; Huang J; Wang J; Zhong W; Chen W; Lin X; Lin X
J Cancer Res Clin Oncol; 2018 May; 144(5):821-833. PubMed ID: 29435734
[TBL] [Abstract][Full Text] [Related]
7. ASCT2 overexpression is associated with poor survival of OSCC patients and ASCT2 knockdown inhibited growth of glutamine-addicted OSCC cells.
Luo Y; Li W; Ling Z; Hu Q; Fan Z; Cheng B; Tao X
Cancer Med; 2020 May; 9(10):3489-3499. PubMed ID: 32162845
[TBL] [Abstract][Full Text] [Related]
8. Lobetyolin inhibits the proliferation of breast cancer cells
Chen Y; Tian Y; Jin G; Cui Z; Guo W; Zhang X; Liu X
Hum Exp Toxicol; 2021 Dec; 40(12):2074-2086. PubMed ID: 34075790
[TBL] [Abstract][Full Text] [Related]
9. Silencing of Girdin suppresses the malignant behavior of colorectal carcinoma cells.
Lu J; Zhang L; Zhou H; Du Z; Zhang G
Oncol Rep; 2018 Aug; 40(2):887-894. PubMed ID: 29989653
[TBL] [Abstract][Full Text] [Related]
10. Glutamine availability up-regulates expression of the amino acid transporter protein ASCT2 in HepG2 cells and stimulates the ASCT2 promoter.
Bungard CI; McGivan JD
Biochem J; 2004 Aug; 382(Pt 1):27-32. PubMed ID: 15175006
[TBL] [Abstract][Full Text] [Related]
11. The glutamine transporter ASCT2 (SLC1A5) promotes tumor growth independently of the amino acid transporter LAT1 (SLC7A5).
Cormerais Y; Massard PA; Vucetic M; Giuliano S; Tambutté E; Durivault J; Vial V; Endou H; Wempe MF; Parks SK; Pouyssegur J
J Biol Chem; 2018 Feb; 293(8):2877-2887. PubMed ID: 29326164
[TBL] [Abstract][Full Text] [Related]
12. Target the human Alanine/Serine/Cysteine Transporter 2(ASCT2): Achievement and Future for Novel Cancer Therapy.
Jiang H; Zhang N; Tang T; Feng F; Sun H; Qu W
Pharmacol Res; 2020 Aug; 158():104844. PubMed ID: 32438035
[TBL] [Abstract][Full Text] [Related]
13. [Silencing HMGB1 expression by lentivirus-mediated small interfering RNA (siRNA) inhibits the proliferation and invasion of colorectal cancer LoVo cells in vitro and in vivo].
Li Z; Wang H; Song B; Sun Y; Xu Z; Han J
Zhonghua Zhong Liu Za Zhi; 2015 Sep; 37(9):664-70. PubMed ID: 26813430
[TBL] [Abstract][Full Text] [Related]
14. Inducible antisense RNA targeting amino acid transporter ATB0/ASCT2 elicits apoptosis in human hepatoma cells.
Fuchs BC; Perez JC; Suetterlin JE; Chaudhry SB; Bode BP
Am J Physiol Gastrointest Liver Physiol; 2004 Mar; 286(3):G467-78. PubMed ID: 14563674
[TBL] [Abstract][Full Text] [Related]
15. Targeting glutamine transport to suppress melanoma cell growth.
Wang Q; Beaumont KA; Otte NJ; Font J; Bailey CG; van Geldermalsen M; Sharp DM; Tiffen JC; Ryan RM; Jormakka M; Haass NK; Rasko JE; Holst J
Int J Cancer; 2014 Sep; 135(5):1060-71. PubMed ID: 24531984
[TBL] [Abstract][Full Text] [Related]
16. Glutamine transporter ASCT2 was down-regulated in ischemic injured human intestinal epithelial cells and reversed by epidermal growth factor.
Huang Q; Li N; Zhu W; Li Q; Li J
JPEN J Parenter Enteral Nutr; 2007; 31(2):86-93. PubMed ID: 17308248
[TBL] [Abstract][Full Text] [Related]
17. Anti-tumor effects of an antagonistic mAb against the ASCT2 amino acid transporter on KRAS-mutated human colorectal cancer cells.
Hara Y; Minami Y; Yoshimoto S; Hayashi N; Yamasaki A; Ueda S; Masuko K; Masuko T
Cancer Med; 2020 Jan; 9(1):302-312. PubMed ID: 31709772
[TBL] [Abstract][Full Text] [Related]
18. ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer.
van Geldermalsen M; Wang Q; Nagarajah R; Marshall AD; Thoeng A; Gao D; Ritchie W; Feng Y; Bailey CG; Deng N; Harvey K; Beith JM; Selinger CI; O'Toole SA; Rasko JE; Holst J
Oncogene; 2016 Jun; 35(24):3201-8. PubMed ID: 26455325
[TBL] [Abstract][Full Text] [Related]
19. Targeting ASCT2-mediated glutamine metabolism inhibits proliferation and promotes apoptosis of pancreatic cancer cells.
Wang W; Pan H; Ren F; Chen H; Ren P
Biosci Rep; 2022 Mar; 42(3):. PubMed ID: 35237783
[TBL] [Abstract][Full Text] [Related]
20. The role of ASCT2 in cancer: A review.
Liu Y; Zhao T; Li Z; Wang L; Yuan S; Sun L
Eur J Pharmacol; 2018 Oct; 837():81-87. PubMed ID: 30025811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
